DENVER--(BUSINESS WIRE)-- In a new Phase III study, BRINAVESS TM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results